First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s3099
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Still a Role for Second-Line Chemoimmunotherapy in Chronic Lymphocytic Leukemia?

Haematologica
Hematology
2018English

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Oncologist
Cancer ResearchMedicineOncology
2008English

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Treatment-Related Acute Myeloid Leukemia in a Chronic Lymphocytic Leukemia Patient: Role of Fludarabine?

Therapeutic Advances in Hematology
Hematology
2015English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)

Oncogematologiya
OncologyHematology
2018English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Economic Cost of Adverse Events Per Course of Therapy With Commonly Used First-Line Regimens for the Treatment of Chronic Lymphocytic Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy